Matches in SemOpenAlex for { <https://semopenalex.org/work/W2760668954> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2760668954 abstract "The objective of the present study was to determine the combined effect of sodium butyrate (NaBu), a histone deacetylase (HDAC) inhibitor and all-trans retinoic acid (ATRA) on attenuation of renal fibrosis and inflammation in Npr1 (coding for natriuretic peptide receptor-A) gene-disrupted mutant mice. Adult (18-20 week old) male Npr1 gene-disrupted heterozygous (1-copy; Npr1+/-) wild-type (2-copy; Npr1+/+), and gene-duplicated (3-copy; Npr1++/+) mice were treated by injecting ATRA-NaBu hybrid drug (1.0 mg/kg/day) intraperitoneally for 2-weeks. A marked attenuation in tubulo-interstitial fibrosis was observed in Npr1+/- mice after treatment with ATRA-NaBu (50%, p < 0.001). Western blot analyses exhibited the reduction in renal expression of collagen type I alpha 2 and transforming growth factor-beta (55%, p < 0.001, 67%, p < 0.001, respectively) in ATRA-NaBu-treated Npr1+/- mice compared with vehicle-treated mice. A significant decrease in systolic blood pressure was observed in ATRA-NaBu-treated Npr1+/- mice (treated 110.3 ± 2.6 vs. Npr1 +/- control mice, 126.3 ± 2.7, p < 0.01). The ATRA-NaBu also enhanced plasma cGMP levels (pmol/ml) in Npr1+/- (treated, 22.7 ± 3.3 vs. control, 6.2 ± 1.6; p < 0.05), Npr1+/+ (treated, 50.9 ± 3.5 vs. control, 20.8 ± 3.6; p < 0.05), and Npr1++/+ (treated, 71.4 ± 6.4 vs. control, 34.5 ± 2.9; p < 0.05) mice. Treatment with ATRA-NaBu significantly lowered renal levels (pg/mg protein) of monocyte chemoattractant protein-1 (MCP-1) (treated, 109.5 ± 9.9 vs. control, 24.3 ± 1.7; p < 0.01) in Npr1+/- mice compared with vehicle-treated mice. Western blot analyses confirmed the reduction in renal expression of MCP-1 (72%, p < 0.001) in ATRA-NaBu-treated Npr1+/- mice compared with control mice. Moreover, the increased HDAC activity in Npr1+/- mice was significantly reduced by ATRA-NaBu treatment compared with untreated Npr1+/- control mice. The present results provide direct evidence that ATRA-NaBu acts as a potent antifibrotic agent and repairs the renal pathology in Npr1+/- mice, which will have important implications in prevention of hypertension-related renal pathophysiological conditions." @default.
- W2760668954 created "2017-10-06" @default.
- W2760668954 creator A5013084644 @default.
- W2760668954 creator A5056077743 @default.
- W2760668954 date "2015-09-01" @default.
- W2760668954 modified "2023-09-23" @default.
- W2760668954 title "Abstract P047: Epigenetic Mechanisms of Sodium Butyrate- and Retinoic Acid-dependent Attenuation of Renal Fibrosis and Inflammation in Npr1 Gene-targeted Mice" @default.
- W2760668954 doi "https://doi.org/10.1161/hyp.66.suppl_1.p047" @default.
- W2760668954 hasPublicationYear "2015" @default.
- W2760668954 type Work @default.
- W2760668954 sameAs 2760668954 @default.
- W2760668954 citedByCount "0" @default.
- W2760668954 crossrefType "journal-article" @default.
- W2760668954 hasAuthorship W2760668954A5013084644 @default.
- W2760668954 hasAuthorship W2760668954A5056077743 @default.
- W2760668954 hasConcept C126322002 @default.
- W2760668954 hasConcept C134018914 @default.
- W2760668954 hasConcept C203014093 @default.
- W2760668954 hasConcept C2522874641 @default.
- W2760668954 hasConcept C2775915353 @default.
- W2760668954 hasConcept C2776175608 @default.
- W2760668954 hasConcept C2776914184 @default.
- W2760668954 hasConcept C2777869810 @default.
- W2760668954 hasConcept C2778198053 @default.
- W2760668954 hasConcept C2780091579 @default.
- W2760668954 hasConcept C2780559512 @default.
- W2760668954 hasConcept C2780593183 @default.
- W2760668954 hasConcept C71924100 @default.
- W2760668954 hasConcept C8741621 @default.
- W2760668954 hasConceptScore W2760668954C126322002 @default.
- W2760668954 hasConceptScore W2760668954C134018914 @default.
- W2760668954 hasConceptScore W2760668954C203014093 @default.
- W2760668954 hasConceptScore W2760668954C2522874641 @default.
- W2760668954 hasConceptScore W2760668954C2775915353 @default.
- W2760668954 hasConceptScore W2760668954C2776175608 @default.
- W2760668954 hasConceptScore W2760668954C2776914184 @default.
- W2760668954 hasConceptScore W2760668954C2777869810 @default.
- W2760668954 hasConceptScore W2760668954C2778198053 @default.
- W2760668954 hasConceptScore W2760668954C2780091579 @default.
- W2760668954 hasConceptScore W2760668954C2780559512 @default.
- W2760668954 hasConceptScore W2760668954C2780593183 @default.
- W2760668954 hasConceptScore W2760668954C71924100 @default.
- W2760668954 hasConceptScore W2760668954C8741621 @default.
- W2760668954 hasIssue "suppl_1" @default.
- W2760668954 hasLocation W27606689541 @default.
- W2760668954 hasOpenAccess W2760668954 @default.
- W2760668954 hasPrimaryLocation W27606689541 @default.
- W2760668954 hasRelatedWork W1982891639 @default.
- W2760668954 hasRelatedWork W2016524695 @default.
- W2760668954 hasRelatedWork W2059573018 @default.
- W2760668954 hasRelatedWork W2128542354 @default.
- W2760668954 hasRelatedWork W2162392154 @default.
- W2760668954 hasRelatedWork W2166972359 @default.
- W2760668954 hasRelatedWork W2268765586 @default.
- W2760668954 hasRelatedWork W2296297408 @default.
- W2760668954 hasRelatedWork W2345988494 @default.
- W2760668954 hasRelatedWork W2418921182 @default.
- W2760668954 hasRelatedWork W2529672150 @default.
- W2760668954 hasRelatedWork W2763903345 @default.
- W2760668954 hasRelatedWork W2771236276 @default.
- W2760668954 hasRelatedWork W2906498568 @default.
- W2760668954 hasRelatedWork W2974973426 @default.
- W2760668954 hasRelatedWork W3042185275 @default.
- W2760668954 hasRelatedWork W3042895760 @default.
- W2760668954 hasRelatedWork W3045782789 @default.
- W2760668954 hasRelatedWork W3165843772 @default.
- W2760668954 hasRelatedWork W3171695339 @default.
- W2760668954 hasVolume "66" @default.
- W2760668954 isParatext "false" @default.
- W2760668954 isRetracted "false" @default.
- W2760668954 magId "2760668954" @default.
- W2760668954 workType "article" @default.